Dr. Llovet on Efficacy of Namodenoson in Child-Pugh B HCC
Josep M. Llovet, MD, PhD
Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses a phase II, double-blind, placebo-controlled trial examining the efficacy and safety of namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment for patients with Child-Pugh B advanced hepatocellular carcinoma (HCC).
In patients with HCC, Child-Pugh B stands for a classification that defines the status of liver failure, Llovet explains.
Prior to this trial, the actions and mechanisms of namodenoson in patients with Child-Pugh B HCC were unknown because all the drugs had been tested in Child-Pugh A patients, according to Llovet. As a result, patients who have Child-Pugh B HCC do not have a standard frontline therapy. Most of the TKIs are toxic in these patients, Llovet explains. Namodenoson has a tolerable safety profile, according to Llovet, and the drug is only being used on Child-Pugh B patients with more preserved liver function.
Results showed that the median overall survival was 4.1 months with namodenoson and 4.3 months in placebo in the intent-to-treat population. Moreover, the median progression-free survival was 2.6 months with namodenoson and 1.9 months with placebo.